Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Armed And Ready For Next 'Pricing' Criticisms

This article was originally published in Scrip

Executive Summary

The next time lawmakers, as they inevitably will, want to blame the FDA for leaving patients with no options but to pay the hiked up prices of older pharmaceuticals because the agency has failed to move quicker on approving generic alternatives, regulators will be armed and ready with a new report, which shows they permitted more than 700 cheaper versions of brand-name medicines onto the US market in 2015 – more than ever before.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts